quinapril has been researched along with Hyperlipidemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, TJ; Cooper, ME; de Gasparo, M; Feng, B; Jandeleit-Dahm, KA; Li, J; Schumacher, C; Thomas, MC; Watson, AM | 1 |
| Brancati, AM; Cangelosi, MM; Gaudio, M; Leggio, F | 1 |
2 other study(ies) available for quinapril and Hyperlipidemias
| Article | Year |
|---|---|
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
Topics: Animals; Antihypertensive Agents; Apolipoproteins E; Atherosclerosis; Blood Pressure; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Endothelin Receptor Antagonists; Hyperglycemia; Hyperlipidemias; Kidney; Kidney Function Tests; Mice; Mice, Knockout; Pyridines; Pyrimidines; Quinapril; Tetrahydroisoquinolines | 2010 |
Blood lipid changes in hypertensive, dyslipidemic patients under long term quinapril treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cholesterol; Female; Humans; Hyperlipidemias; Hypertension; Isoquinolines; Lipids; Lipoproteins, LDL; Male; Middle Aged; Quinapril; Tetrahydroisoquinolines; Triglycerides | 1994 |